معرفی
Dr. Nada Lallous serves as an Assistant Professor in the Department of Urologic Sciences at the University of British Columbia's Faculty of Medicine and Senior Research Scientist at the Vancouver Prostate Centre. Her research focuses on cancer drug development, particularly targeting molecular mechanisms of prostate cancer progression, metastasis, and therapeutic resistance through biochemical and biophysical approaches.
Her educational background includes a M.Sc and Ph.D in Structural Biochemistry and Biophysics from the University of Strasbourg and the Institute of Genetics and Molecular and Cellular Biology (IGBMC) in France, followed by postdoctoral training at the Spanish National Cancer Research Centre (CNIO). She joined the Vancouver Prostate Centre in 2012 and was appointed Research Scientist in 2017.
Dr. Lallous' research expertise spans cancer biology, protein biochemistry, drug design, and structural biology. She has extensive experience in protein characterization, X-ray crystallography (contributing to 20 Protein Data Bank structures), and preclinical validation of novel inhibitors. Key interests include androgen receptor signaling, transcription factors, biomolecular condensates, and overcoming therapeutic resistance in prostate and breast cancers through targeting molecular drivers like Lin28 and Myc.
Analysis of her 2023-2025 publications reveals a dominant focus on androgen receptor (AR) biology in prostate cancer, with significant emphasis on AR variants (AR-V7), phase separation phenomena, and development of novel inhibitors targeting AR domains, Lin28-let-7 interactions, and Myc-Max dimerization. Her work integrates computational drug design, structural biology, and functional validation to address therapeutic resistance.
Dr. Lallous has secured competitive funding including an NIH-SPORE grant from the National Cancer Institute to study androgen receptor variants in circulating tumor DNA. She mentors graduate students in UBC's Experimental Medicine program, including PhD candidate Louise Ramos working on bifunctional PARP-HDAC inhibitors. She actively collaborates with pharmaceutical companies on drug development projects.
As manager of the protein bioengineering and biophysics group at the Vancouver Prostate Centre, Dr. Lallous is establishing a core facility to support preclinical drug validation and structural studies for cancer researchers, enabling high-throughput inhibitor screening and biophysical characterization.
